Serological responses triggered by different SARS-CoV-2 vaccines against SARS-CoV-2 variants in Taiwan
Broadly neutralizing ability is critical for developing the next-generation SARS-CoV-2 vaccine. We collected sera samples between December 2021-January 2022 from 113 Taiwan naïve participants after their second dose of homologous vaccine (AZD1222, mRNA-1273, BNT162-b2, and MVC-COV1901) and compared...
Main Authors: | Chiao-Hsuan Chao, Dayna Cheng, Sheng-Wen Huang, Yung-Chun Chuang, Trai-Ming Yeh, Jen-Ren Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1023943/full |
Similar Items
-
Neutralizing and enhancing antibodies against SARS-CoV-2
by: Yafei Liu, et al.
Published: (2022-12-01) -
Enhancement of NETosis by ACE2-cross-reactive anti-SARS-CoV-2 RBD antibodies in patients with COVID-19
by: Kun-Han Hsieh, et al.
Published: (2024-04-01) -
Comparison of Six Serological Immunoassays for the Detection of SARS-CoV-2 Neutralizing Antibody Levels in the Vaccinated Population
by: Hee-Jung Lee, et al.
Published: (2022-04-01) -
Serological Tests in the Detection of SARS-CoV-2 Antibodies
by: Kissy Guevara-Hoyer, et al.
Published: (2021-04-01) -
Post-SARS-CoV-2 infection and post-vaccine-related neurological complications share clinical features and the same positivity to anti-ACE2 antibodies
by: Margherita Bellucci, et al.
Published: (2024-08-01)